This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05493501
Recruitment Status : Terminated (The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with aumolertinib.)
First Posted : August 9, 2022
Last Update Posted : October 6, 2023
Sponsor:
Information provided by (Responsible Party):
EQRx International, Inc.

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : August 31, 2023
Actual Study Completion Date : August 31, 2023
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 November 1, 2023
November 20, 2023 Submission with QC Comments
2 November 28, 2023
December 4, 2023 Submission with QC Comments
3 April 9, 2024